Market research
4AJ.F ALK-Abelló A/S
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 82B
- P/E ratio
- 2753.38
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.32
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 82B
- P/E ratio
- 2753.38
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.32
About
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4AJ.F discussion.
5 years, 5 months ago
ALK-Abelló A/S is currently in a long term uptrend where the price is trading 24.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.4.
ALK-Abelló A/S's total revenue rose by 12.2% to $991M since the same quarter in the previous year.
Its net income has dropped by 6.9% to $-31M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.4% to $136M since the same quarter in the previous year.
Based on the above factors, ALK-Abelló A/S gets an overall score of 4/5.